Mammography Devices Market Summary The global mammography devices market is expected to increase from USD 2,671.77 million in 2025 to USD 5,427.49 million by 2034, reflecting strong and sustained growth. The global mammography devices market is growing at a CAGR of 8.25% during the forecast period ...

Stress Urinary Incontinence Devices Market Summary The global stress urinary incontinence devices market is expected to increase from 2,232.79 million in 2025 to 3,929.46 million by 2034, reflecting strong and sustained growth. The global stress urinary incontinence devices market is growing at a CA ...

Urinary Catheters Market Summary The global urinary catheters market is expected to increase from USD 4,464.41 million in 2025 to USD 7,747.60 million by 2034, reflecting strong and sustained growth. The global urinary catheters market is growing at a CAGR of 6.36% during the forecast period from 20 ...

Laparoscopy Devices Market Summary The global laparoscopy devices market is expected to increase from USD 11,172.39 million in 2025 to USD 23,593.31 million by 2034, reflecting strong and sustained growth. The global laparoscopy devices market is growing at a CAGR of 8.73% during the forecast period ...

Neurovascular Devices Market Summary The global neurovascular devices market is expected to increase from USD 3,904.74 million in 2025 to USD 8,044.66 million by 2034, reflecting strong and sustained growth. The global neurovascular devices market is growing at a CAGR of 8.40% during the forecast pe ...

Perfusion Systems Market Summary The global perfusion systems market is expected to increase from USD 1,528.52 million in 2025 to USD 2,443.52 million by 2034, reflecting strong and sustained growth. The global perfusion systems market is growing at a CAGR of 5.41% during the forecast period from ...

Key Factors Driving Bedaquiline Growth 1. Rising Global Burden of Drug-Resistant Tuberculosis A major factor fueling bedaquiline’s growth is the persistent and increasing incidence of multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB) — strains that do not respond to standard ...

Key Factors Driving EOHILIA Growth 1. Regulatory Milestone: First FDA-Approved Oral EoE Therapy EOHILIA received FDA approval on February 2024 as the first and only FDA-approved oral treatment for eosinophilic esophagitis (EoE) in patients aged ≥ 11 years, delivering a targeted budesonide oral suspe ...

Key Factors Driving TPN-101 Growth 1. Novel Mechanism Targeting Neurodegeneration TPN-101 is a first-in-class LINE-1 reverse transcriptase inhibitor, designed to block activity of LINE-1 retrotransposable elements, which are implicated in neurodegenerative disease pathology such as amyotrophic later ...

Fetal Monitoring Devices Market Summary The global fetal monitoring devices market is expected to increase from USD 4,148.39 million in 2025 to USD 7,176.97 million by 2034, reflecting strong and sustained growth. The global fetal monitoring devices market is growing at a CAGR of 6.34% during the fo ...

Teleradiology Market Summary The global teleradiology market is expected to increase from USD 10,236.87 million in 2025 to USD 33,891.12 million by 2034, reflecting strong and sustained growth. The global teleradiology market is growing at a CAGR of 14.26% during the forecast period from 2026 to 203 ...

Key Factors Driving VOYDEYA Growth 1. Strategic Approvals and Regulatory Successes VOYDEYA has received approvals in major regions: Japan: First regulatory approval for adults with PNH, in combination with C5 inhibitors, based on the pivotal ALPHA Phase III trial. United States: FDA approved VOYDEYA ...

Key Factors Driving APT-1011 Growth 1. Addressing a Significant Unmet Need in Eosinophilic Esophagitis APT-1011 is an investigational, once-daily oral disintegrating tablet of fluticasone propionate designed to deliver topical anti-inflammatory effects to the esophagus with minimal systemic exposure ...

Key Factors Driving CNM-Au8 Growth 1. Promising Survival Benefits in ALS Clinical Data Recent post-hoc analyses of the HEALEY ALS Platform Trial suggest strong survival benefits for ALS patients treated with CNM-Au8: Participants treated with CNM-Au8 had median survival improvements — in some analys ...

Key Factors Driving Pridopidine Growth 1. Clinical Evidence Suggesting Disease-Modifying Effects in Huntington’s Disease Results from the Phase III PROOF-HD trial — published in Nature Medicine — showed that pridopidine slowed clinical progression and maintained function, cognition, and motor perfor ...

Orthotics Devices Market Summary The global orthotics devices market is expected to increase from USD 3,469.40 million in 2025 to USD 5,546.23 million by 2034, reflecting strong and sustained growth. The global orthotics devices market is growing at a CAGR of 5.41% during the forecast period from 20 ...

Urinary Tract Obstruction Treatment Devices Market Summary The global urinary tract obstruction treatment devices market is expected to increase from USD 6,515.92 million in 2025 to USD 11,358.52 million by 2034, reflecting strong and sustained growth. The global urinary tract obstruction treatment ...

Needle Safety Devices Market Summary The global needle safety devices market is expected to increase from USD 2,284.15 million in 2025 to USD 3,637.49 million by 2034, reflecting strong and sustained growth. The global needle safety devices market is growing at a CAGR of 5.39% during the forecast pe ...

Foot Drop Treatment Devices Market Summary The global foot drop treatment devices market is expected to increase from USD 1,917.55 million in 2025 to USD 2,954.85 million by 2034, reflecting strong and sustained growth. The global foot drop treatment devices market is growing at a CAGR of 4.98% duri ...

Nuclear Medicine (Radiopharmaceuticals) Market Summary The global nuclear medicine (radiopharmaceuticals) market is expected to increase from USD 10,746.92 million in 2025 to USD 24,152.35 million by 2034, reflecting strong and sustained growth. The global nuclear medicine (radiopharmaceuticals) mar ...

Key Factors Driving KYV-101 Growth 1. Registrational and Regulatory Advancement in Key Autoimmune Indications KYV-101 is progressing through registrational clinical programs with clear regulatory alignment with the US FDA: Stiff Person Syndrome (SPS): Kyverna completed enrollment in the registration ...

Key Factors Driving RAPA-501 Growth 1. Development in a High-Unmet Medical Need (ALS) ALS is a rapidly progressive, fatal neurodegenerative disease with very limited effective treatments. Current standards like riluzole, edaravone and sodium phenylbutyrate/taurursodiol modestly slow progression but ...

Key Factors Driving Cendakimab Growth 1. Clinical Validation in Eosinophilic Esophagitis (EoE) Cendakimab (anti–IL-13 monoclonal antibody developed by Bristol Myers Squibb) has demonstrated statistically significant improvements in symptoms, histologic response and endoscopic features in patients wi ...

Key Factors Driving TEZSPIRE Growth 1. Demonstrated Clinical Value Across Broad Severe Asthma Populations TEZSPIRE has shown significant reductions in asthma exacerbations across biomarker subgroups, irrespective of eosinophil levels or allergic status — supporting treatment of a broad severe asthma ...